Delving into the Latest Updates on Huaier Granule with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Frailty Syndrome

Inactive Indication

Stage III Colon Cancer

Originator Organization

Qidong Gaitianli Medicines Co., Ltd.

Active Organization

Qidong Gaitianli Medicines Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (24 Jun 2020),

Frailty Syndrome

Regulation-

Login to view timeline

BACKGROUNDTriple-negative breast cancer (TNBC) is the most intractable subgroup of breast neoplasms due to its aggressive nature. In recent years, immune checkpoint inhibitors (ICIs) have exhibited potential efficacy in TNBC treatment. However, only a limited fraction of patients benefit from ICI therapy, primarily because of the suppressive tumor immune microenvironment (TIME). Trametes robiniophila Murr (Huaier) is a traditional Chinese medicine (TCM) with potential immunoregulatory functions. However, the underlying mechanism remains unclear.PURPOSEThe present study aimed to investigate the therapeutic role of Huaier in the TIME of TNBC patients.METHODSSingle-cell RNA sequencing (scRNA-seq) was used to systematically analyze the influence of Huaier on the TNBC microenvironment for the first time. The mechanisms of the Huaier-induced suppression of cancer-associated fibroblasts (CAFs) were assessed via real-time quantitative polymerase chain reaction (qRT‒PCR) and western blotting. A tumor-bearing mouse model was established to verify the effects of the oral administration of Huaier on immune infiltration.RESULTSUnsupervised clustering of the transcriptional profiles suggested an increase in the number of apoptotic cancer cells in the Huaier group. Treatment with Huaier induced immunological alterations from a "cold" to a "hot" state, which was accompanied by phenotypic changes in CAFs. Mechanistic analysis revealed that Huaier considerably attenuated the formation of myofibroblastic CAFs (myoCAFs) by impairing transforming growth factor-beta (TGF-β)/SMAD signaling. In mouse xenograft models, Huaier dramatically modulated CAF differentiation, thus synergizing with the programmed cell death 1 (PD1) blockade to impede tumor progression.CONCLUSIONSOur findings demonstrate that Huaier regulates cancer immunity in TNBC by suppressing the transition of CAFs to myoCAFs and emphasize the crucial role of Huaier as an effective adjuvant agent in immunotherapy.

01 Dec 2024·Molecular Biology Reports

Huaier inhibits cholangiocarcinoma cells through the twist1/FBP1/Wnt/β-catenin axis

Article

Author: Zhao, Jing ; Cong, Liyuan ; Li, Kun ; Zhang, Bingyuan ; Dai, Dongdong ; Zhao, Wei ; Shi, Jian

BACKGROUNDAlthough Huaier granules can be used as prospective anti-cholangiocarcinoma drugs, the mechanism of action of Huaier granules in cholangiocarcinoma is not clear. The anti-cholangiocarcinoma effect of Huaier granules was validated in cell line research. In vitro experiments were conducted to investigate the signalling pathways affected by Huaier in CCA cells.METHODS AND RESULTSReal-time quantitative PCR (RT‒qPCR) and Western blot analysis were performed to analyse gene expression in CCA cells. MTT assays, scratch tests, and Transwell assays were used to explore the effects on the proliferation and metastasis of CCA cells. Chromatin immunoprecipitation assays were performed to reveal the potential underlying mechanisms involved. Twist1 was upregulated in human CCA tissues. In addition, its expression levels were negatively related to FBP1 expression levels. Mechanistically, Twist1 can bind to the region of the FBP1 promoter to reduce its expression. Huaier plays an indispensable role in suppressing Twist1 expression to inhibit the Twist1/FBP1/Wnt/β-catenin axis. Then, we verified the effect of Huaier in vitro.CONCLUSIONSThese findings suggested that Huaier granules were capable of inhibiting CCA development through regulating the Twist1/FBP1/Wnt/β-catenin signalling axis and provided a novel orientation for the development of novel anti-CCA drugs.

01 Nov 2024·Journal of Ethnopharmacology

The role and molecular mechanism of Trametes Robiniophila Murr(Huaier) in tumor therapy

Review

Author: Ma, Wei ; Ji, Hao ; Zheng, Aiyu ; Tang, Dong

ETHNOPHARMACOLOGICAL RELEVANCETrametes Robiniophila Murr, commonly known as Huaier, has been extensively documented in ethnopharmacology research in China. Huaier has a long history of clinical usage spanning over 1000 years in China. Traditional clinical application records demonstrate the wide utilization of Huaier for treating various cancers and enhancing the autoimmunity of tumor patients.AIM OF THE REVIEWThe present study provides a comprehensive review of the traditional uses, phytochemical constituents, pharmacological activities, anti-tumor mechanism, and potential applications of Huaier, thereby offering valuable insights for the further development and utilization of this natural product.MATERIALS AND METHODSThis study employed the keywords "Trametes Robiniophila Murr" and "Huaier" to retrieve relevant information on Huaier from various databases, including PubMed, Web of Science, Springer, Science Direct, ACS, Wiley, CNKI, Baidu Scholar, Google Scholar, and ancient materia medica.RESULTSTrametes Robiniophila Murr (Huaier), a traditional Chinese medicine, has demonstrated significant efficacy in the clinical treatment of various tumors. The primary bioactive constituents of Huaier consist of fungal-derived compounds, including polysaccharides, proteins, ketones, alkaloids, and minerals. The research findings demonstrate that Huaier serves as a reliable adjunctive therapeutic agent by effectively inhibiting cancer cell proliferation, inducing apoptosis in cancer cells, suppressing tumor metastasis, regulating tumor stem cells and immune function. Therefore, it exerts a potent anti-tumor effect when used in conjunction with conventional anti-cancer therapies.CONCLUSIONSThe analysis of traditional uses, phytochemical composition, and pharmacological activity reveals that Huaier exhibits significant potential as a medicinal plant with diverse pharmacological effects. Owing to its numerous advantages, Huaier holds immense promise for application in the domains of tumor prevention and treatment, enhancing both survival time and quality of life among cancer patients.

100 Deals associated with Huaier Granule

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Frailty Syndrome	CN	Qidong Gaitianli Medicines Co., Ltd.	24 Jun 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2023	Not Applicable	Hepatocellular Carcinoma	-	Huaier granule group	(kcloedxdky) = gnjbweqjiy ghheqdxiet (lpvoomwgii )	Positive	31 May 2023
				Huaier granules (Control group)	(kcloedxdky) = qbzpitbkhh ghheqdxiet (lpvoomwgii )
CSCO2020	Not Applicable	Hepatocellular Carcinoma Adjuvant	340	Huaier granules (Single thermal ablation)	sbxmruywjs(wobvmlxwin) = The combined treatment group presented more obvious nausea and emesis side effects, but the differences were not statistically significant thecrzodvk (vpzbwlruge )	-	19 Sep 2020
EASL2019	Phase 4	Hepatocellular Carcinoma Adjuvant	-	Huaier granule	ylmrfiuyty(bjynbtzsff) = qsfmnqqydy zadghddljm (tvjaohntpd ) View more	Positive	12 Apr 2019
				huaier granule	ylmrfiuyty(bjynbtzsff) = pcdpibaqxz zadghddljm (tvjaohntpd ) View more
NCT01770431 (Pubmed \| Gut)	Phase 4	Recurrent Carcinoma Adjuvant	1,044	Huaier granule	(xpruvcjcpa) = olizeocket fphmnlegdw (sfjaxopbxx ) View more	Positive	01 Nov 2018
				Huaier granule (No further treatment)	(xpruvcjcpa) = ewptvgdjid fphmnlegdw (sfjaxopbxx ) View more
WCLC2018	Not Applicable	Adenocarcinoma of Lung	40	Huaier Aqueous Extract	khsqeiatgl(rfrapeeotx) = fhzzfsalwq owzbcehpid (xwioyoqsfm )	-	24 Sep 2018
NCT01770431 (CTgov)	Phase 4	Hepatocellular Carcinoma	1,044	Huaier Granule (Huaier Granule Group)	ztyyaqjpdf(iajmluqrcx): chi-squared = 14.7315, P-Value = 0.0001 View more	-	02 Oct 2017
				Huaier Granule (Bank-control Group)